Naxitamab

Naxitamab, sold under the brand name Danyelza, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy.[2][3]

Naxitamab
Monoclonal antibody
TypeWhole antibody
TargetGD2
Clinical data
Trade namesDanyelza
Other namesnaxitamab-gqgk
License data
Routes of
administration		Intravenous
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6414H9910N1718O1996S44
Molar mass144436.50 g·mol−1

The most common adverse reactions include infusion-related reactions, pain, tachycardia (fast heart beats), vomiting, cough, nausea, diarrhea, decreased appetite, hypertension, fatigue, erythema multiforme, peripheral neuropathy, urticaria, pyrexia, headache, injection site reaction, edema, anxiety, localized edema, and irritability.[2][4]

The U.S. Food and Drug Administration (FDA) granted the application for naxitamab priority review, breakthrough therapy, and, orphan drug designations.[2] The FDA issued a priority review voucher for this rare pediatric disease product application[2] and was later granted a priority approval.[5]

Medical uses

Naxitamab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat people one year of age and older with high-risk neuroblastoma in bone or bone marrow whose tumor did not respond to or has come back after previous treatments and has shown a partial response, minor response, or stable disease to prior therapy.[4]

History

The application for naxitamab was approved based on two clinical trials (Trial 1/NCT03363373 and Trial 2/NCT01757626) of 97 participants with high-risk neuroblastoma in bone or bone marrow.[4] The trials were conducted at four centers in the United States and in Spain.[4] Both trials enrolled participants who were previously treated for high-risk neuroblastoma in the bone or bone marrow.[4] Some participants were not responding to the previous therapies anymore and some participants experienced the return of the cancer.[4] Participants with cancer that was actively growing after their last therapy were not included in the trial.[4] All participants received naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) according to the trial schedule.[4]

Society and culture

Naxitamab was approved for medical use in the United States in November 2020.[6][7]

References
  1. "Danyelza- naxitamab injection". DailyMed. Retrieved 22 May 2021.
  2. "FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow". U.S. Food and Drug Administration (FDA) (Press release). 25 November 2020. Retrieved 25 November 2020. This article incorporates text from this source, which is in the public domain.
  3. "FDA Approves Y-mAbs' Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma" (Press release). Y-mAbs Therapeutics. 25 November 2020. Retrieved 25 November 2020 – via GlobeNewswire.
  4. "Drugs Trials Snapshot: Danyelza". U.S. Food and Drug Administration (FDA). 25 November 2020. Retrieved 25 December 2020. This article incorporates text from this source, which is in the public domain.
  5. Markham A (February 2021). "Naxitamab: First Approval". Drugs. 81 (2): 291–296. doi:10.1007/s40265-021-01467-4. PMID 33616889. S2CID 231981814.
  6. "Naxitamab: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 29 November 2020.
  7. "Drug Approval Package: Danyelza". U.S. Food and Drug Administration (FDA). 22 December 2020. Retrieved 25 December 2020.
  • "Naxitamab". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT03363373 for "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow" at ClinicalTrials.gov
  • Clinical trial number NCT01757626 for "Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.